Chinese General Practice ›› 2024, Vol. 27 ›› Issue (19): 2364-2374.DOI: 10.12114/j.issn.1007-9572.2023.0472
Special Issue: 内分泌代谢性疾病最新文章合辑; 老年人群健康最新文章合辑; 老年问题最新文章合辑
• Article • Previous Articles Next Articles
Received:
2023-06-14
Revised:
2024-02-26
Published:
2024-07-05
Online:
2024-04-28
Contact:
ZHU Hong
通讯作者:
朱宏
作者简介:
作者贡献:
黄书玮参与文章构思与设计、数据收集与管理、论文写作;周志衡、冯天元、刘莉参与文章构思与设计、数据收集与管理、论文修订;邓光璞、李尧天参与文章构思与设计、统计分析、审查和论文写作;朱宏负责文章构思与设计、文章的质量控制及审校,对文章整体负责。
基金资助:
CLC Number:
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.chinagp.net/EN/10.12114/j.issn.1007-9572.2023.0472
序号 | 公式 |
---|---|
式(1) | BMI=体质量/身高2 |
式(2) | TyG指数=ln[TG×FBG/2] |
式(3) | TyG-BMI指数=TyG指数×BMI |
式(4) | TyG-WC指数=TyG指数×WC |
式(5) | TG/HDL-C指数=TG/HDL-C |
式(6) | Non-HDL-C/HDL-C指数=(TC-HDL-C)/HDL-C |
式(7) | METS-IR指数= {ln[2×FPG+TG]×BMI/ln [HDL-C]} |
式(8) | LCI指数=TC×TG×LDL-C/HDL-C |
式(9) | CI指数=(LDL-C-HDL-C)(TG<400 mg/dL)或LDL-C-HDL-C+TG/5(TG≥400 mg/dL) |
Table 1 Indicator calculation formula
序号 | 公式 |
---|---|
式(1) | BMI=体质量/身高2 |
式(2) | TyG指数=ln[TG×FBG/2] |
式(3) | TyG-BMI指数=TyG指数×BMI |
式(4) | TyG-WC指数=TyG指数×WC |
式(5) | TG/HDL-C指数=TG/HDL-C |
式(6) | Non-HDL-C/HDL-C指数=(TC-HDL-C)/HDL-C |
式(7) | METS-IR指数= {ln[2×FPG+TG]×BMI/ln [HDL-C]} |
式(8) | LCI指数=TC×TG×LDL-C/HDL-C |
式(9) | CI指数=(LDL-C-HDL-C)(TG<400 mg/dL)或LDL-C-HDL-C+TG/5(TG≥400 mg/dL) |
组别 | 例数 | 性别[例(%)] | 高血压[例(%)] | 吸烟[例(%)] | |||
---|---|---|---|---|---|---|---|
男 | 女 | 否 | 是 | 否 | 是 | ||
NHUA组 | 1 528 | 838(54.84) | 690(45.16) | 775(49.28) | 753(50.72) | 1 131(74.02) | 387(25.98) |
HUA组 | 479 | 336(70.15) | 143(29.85) | 184(38.41) | 295(61.59) | 334(69.73) | 145(30.27) |
χ2值 | 35.177 | 22.136 | 3.403 | ||||
P值 | <0.001 | <0.001 | 0.065 | ||||
组别 | 饮酒[例(%)] | 运动[例(%)] | 年龄( | T2DM病程( | WC( | ||
否 | 是 | 否 | 是 | ||||
NHUA组 | 1 326(86.13) | 212(13.87) | 856(56.02) | 672(43.98) | 57.74±11.15 | 70.86±79.77 | 0.87±0.08 |
HUA组 | 401(83.72) | 78(16.28) | 243(50.73) | 236(49.27) | 57.62±12.16 | 69.23±66.01 | 0.95±0.06 |
χ2(t)值 | 1.713a | 4.12a | -0.197 | -0.404 | 19.539 | ||
P值 | 0.191 | 0.042 | 0.844 | 0.686 | <0.001 | ||
组别 | BMI( | SBP( | DBP( | FPG( | HbA1c( | ALT( | AST( |
NHUA组 | 24.18±2.63 | 130±15 | 79±9 | 7.46±1.45 | 7.48±1.70 | 25.29±6.64 | 22.57±7.02 |
HUA组 | 26.02±2.97 | 132±15 | 81±9 | 8.01±2.48 | 7.63±2.05 | 27.65±5.05 | 23.82±5.67 |
t值 | 12.969 | 3.211 | 3.738 | 5.925 | 0.878 | 1.804 | 1.467 |
P值 | <0.001 | 0.001 | <0.001 | <0.001 | 0.38 | 0.071 | 0.143 |
组别 | Scr( | TC( | TG( | LDL-C( | HDL-C( | TyG指数( | TyG-BMI指数( |
NHUA组 | 68.87±16.54 | 5.01±1.01 | 1.60±1.22 | 3.10±0.97 | 1.53±0.58 | 9.02±0.66 | 218.27±29.52 |
HUA组 | 85.91±25.49 | 5.16±0.98 | 2.66±1.63 | 3.93±1.51 | 1.19±0.35 | 9.49±0.70 | 247.08±35.58 |
t值 | 8.37 | 2.835 | 14.014 | 2.133 | -18.025 | 14.626 | 17.711 |
P值 | <0.001 | 0.005 | <0.001 | 0.033 | <0.001 | <0.001 | <0.001 |
组别 | TyG-WC指数( | TG/HDL-C指数( | Non-HDL-C/HDL-C指数( | METS IR指数( | LCI指数( | CI指数( | |
NHUA组 | 7.89±0.98 | 2.59±1.64 | 2.40±0.90 | 35.90±5.05 | 65 760.34±57 498.98 | 60.66±39.75 | |
HUA组 | 9.03±0.88 | 5.91±3.61 | 3.60±1.85 | 42.77±7.25 | 176 633.54±368 874.82 | 105.97±58.56 | |
t值 | 22.844 | 15.92 | 19.049 | 23.215 | 11.324 | 3.004 | |
P值 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 |
Table 2 Comparison of general information and clinical data between HUA group and NHUA group
组别 | 例数 | 性别[例(%)] | 高血压[例(%)] | 吸烟[例(%)] | |||
---|---|---|---|---|---|---|---|
男 | 女 | 否 | 是 | 否 | 是 | ||
NHUA组 | 1 528 | 838(54.84) | 690(45.16) | 775(49.28) | 753(50.72) | 1 131(74.02) | 387(25.98) |
HUA组 | 479 | 336(70.15) | 143(29.85) | 184(38.41) | 295(61.59) | 334(69.73) | 145(30.27) |
χ2值 | 35.177 | 22.136 | 3.403 | ||||
P值 | <0.001 | <0.001 | 0.065 | ||||
组别 | 饮酒[例(%)] | 运动[例(%)] | 年龄( | T2DM病程( | WC( | ||
否 | 是 | 否 | 是 | ||||
NHUA组 | 1 326(86.13) | 212(13.87) | 856(56.02) | 672(43.98) | 57.74±11.15 | 70.86±79.77 | 0.87±0.08 |
HUA组 | 401(83.72) | 78(16.28) | 243(50.73) | 236(49.27) | 57.62±12.16 | 69.23±66.01 | 0.95±0.06 |
χ2(t)值 | 1.713a | 4.12a | -0.197 | -0.404 | 19.539 | ||
P值 | 0.191 | 0.042 | 0.844 | 0.686 | <0.001 | ||
组别 | BMI( | SBP( | DBP( | FPG( | HbA1c( | ALT( | AST( |
NHUA组 | 24.18±2.63 | 130±15 | 79±9 | 7.46±1.45 | 7.48±1.70 | 25.29±6.64 | 22.57±7.02 |
HUA组 | 26.02±2.97 | 132±15 | 81±9 | 8.01±2.48 | 7.63±2.05 | 27.65±5.05 | 23.82±5.67 |
t值 | 12.969 | 3.211 | 3.738 | 5.925 | 0.878 | 1.804 | 1.467 |
P值 | <0.001 | 0.001 | <0.001 | <0.001 | 0.38 | 0.071 | 0.143 |
组别 | Scr( | TC( | TG( | LDL-C( | HDL-C( | TyG指数( | TyG-BMI指数( |
NHUA组 | 68.87±16.54 | 5.01±1.01 | 1.60±1.22 | 3.10±0.97 | 1.53±0.58 | 9.02±0.66 | 218.27±29.52 |
HUA组 | 85.91±25.49 | 5.16±0.98 | 2.66±1.63 | 3.93±1.51 | 1.19±0.35 | 9.49±0.70 | 247.08±35.58 |
t值 | 8.37 | 2.835 | 14.014 | 2.133 | -18.025 | 14.626 | 17.711 |
P值 | <0.001 | 0.005 | <0.001 | 0.033 | <0.001 | <0.001 | <0.001 |
组别 | TyG-WC指数( | TG/HDL-C指数( | Non-HDL-C/HDL-C指数( | METS IR指数( | LCI指数( | CI指数( | |
NHUA组 | 7.89±0.98 | 2.59±1.64 | 2.40±0.90 | 35.90±5.05 | 65 760.34±57 498.98 | 60.66±39.75 | |
HUA组 | 9.03±0.88 | 5.91±3.61 | 3.60±1.85 | 42.77±7.25 | 176 633.54±368 874.82 | 105.97±58.56 | |
t值 | 22.844 | 15.92 | 19.049 | 23.215 | 11.324 | 3.004 | |
P值 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 |
变量 | B | SE | OR(95%CI) | Wald χ2值 | P值 |
---|---|---|---|---|---|
性别(以男性为对照) | |||||
女性 | -0.660 | 0.112 | 0.517(0.415~0.644) | 34.533 | <0.001 |
吸烟(以不吸烟为对照) | |||||
吸烟 | 0.213 | 0.115 | 1.237(0.987~1.550) | 3.397 | 0.065 |
饮酒(以不喝酒为对照) | |||||
喝酒 | 0.189 | 0.144 | 1.207(0.910~1.602) | 1.709 | 0.191 |
运动(以不锻炼为对照) | |||||
锻炼 | 0.213 | 0.105 | 0.808(0.658~0.993) | 4.113 | 0.043 |
高血压(以非高血压为对照) | |||||
高血压 | 0.501 | 0.107 | 1.650(1.338~2.035) | 21.921 | <0.001 |
年龄 | -0.001 | 0.005 | 0.999(0.990~1.008) | 0.039 | 0.844 |
病程 | 0.000 | 0.001 | 1.000(0.998~1.001) | 0.163 | 0.686 |
WC | 0.145 | 0.009 | 1.156(1.136~1.176) | 263.989 | <0.001 |
BMI | 0.233 | 0.020 | 1.262(1.214~1.312) | 136.975 | <0.001 |
SBP | 0.011 | 0.004 | 1.011(1.004~1.019) | 10.207 | 0.001 |
DBP | 0.021 | 0.006 | 1.021(1.010~1.033) | 13.766 | <0.001 |
FPG | 0.162 | 0.028 | 1.176(1.112~1.244) | 32.427 | <0.001 |
HbA1c | 0.012 | 0.014 | 1.012(0.984~1.040) | 0.675 | 0.411 |
ALT | 0.003 | 0.002 | 1.003(0.999~1.007) | 2.733 | 0.098 |
AST | 0.004 | 0.003 | 1.004(0.998~1.010) | 1.862 | 0.172 |
Scr | 0.016 | 0.002 | 1.016(1.012~1.020) | 60.549 | <0.001 |
TC | 0.144 | 0.051 | 1.154(1.044~1.276) | 7.902 | 0.005 |
TG | 0.645 | 0.053 | 1.905(1.716~2.115) | 146.439 | <0.001 |
LDL-C | 0.149 | 0.055 | 1.161(1.041~1.294) | 7.239 | 0.007 |
HDL-C | -3.699 | 0.223 | 0.250(0.160~0.380) | 275.394 | <0.001 |
TyG指数 | 1.213 | 0.094 | 3.365(2.796~4.049) | 165.149 | <0.001 |
TyG-BMI指数 | 0.028 | 0.002 | 1.029(1.025~1.032) | 221.724 | <0.001 |
TyG-WC指数 | 1.310 | 0.074 | 3.705(3.204~4.285) | 311.638 | <0.001 |
TG/HDL-C指数 | 0.398 | 0.027 | 1.489(1.411~1.571) | 211.636 | <0.001 |
Non-HDL-C/HDL-C指数 | 1.110 | 0.063 | 3.034(2.680~3.436) | 126.324 | <0.001 |
METS_IR指数 | 0.205 | 0.012 | 1.228(1.200~1.256) | 308.428 | <0.001 |
LCI指数 | 0.000 | 0.000 | 1.000(1.000~1.000) | 169.924 | <0.001 |
CI指数 | 0.014 | 0.002 | 1.014(1.011~1.017) | 75.331 | <0.001 |
Table 3 Univariate Logistic regression analysis of HUA occurrence in middle-aged and elderly T2DM patients
变量 | B | SE | OR(95%CI) | Wald χ2值 | P值 |
---|---|---|---|---|---|
性别(以男性为对照) | |||||
女性 | -0.660 | 0.112 | 0.517(0.415~0.644) | 34.533 | <0.001 |
吸烟(以不吸烟为对照) | |||||
吸烟 | 0.213 | 0.115 | 1.237(0.987~1.550) | 3.397 | 0.065 |
饮酒(以不喝酒为对照) | |||||
喝酒 | 0.189 | 0.144 | 1.207(0.910~1.602) | 1.709 | 0.191 |
运动(以不锻炼为对照) | |||||
锻炼 | 0.213 | 0.105 | 0.808(0.658~0.993) | 4.113 | 0.043 |
高血压(以非高血压为对照) | |||||
高血压 | 0.501 | 0.107 | 1.650(1.338~2.035) | 21.921 | <0.001 |
年龄 | -0.001 | 0.005 | 0.999(0.990~1.008) | 0.039 | 0.844 |
病程 | 0.000 | 0.001 | 1.000(0.998~1.001) | 0.163 | 0.686 |
WC | 0.145 | 0.009 | 1.156(1.136~1.176) | 263.989 | <0.001 |
BMI | 0.233 | 0.020 | 1.262(1.214~1.312) | 136.975 | <0.001 |
SBP | 0.011 | 0.004 | 1.011(1.004~1.019) | 10.207 | 0.001 |
DBP | 0.021 | 0.006 | 1.021(1.010~1.033) | 13.766 | <0.001 |
FPG | 0.162 | 0.028 | 1.176(1.112~1.244) | 32.427 | <0.001 |
HbA1c | 0.012 | 0.014 | 1.012(0.984~1.040) | 0.675 | 0.411 |
ALT | 0.003 | 0.002 | 1.003(0.999~1.007) | 2.733 | 0.098 |
AST | 0.004 | 0.003 | 1.004(0.998~1.010) | 1.862 | 0.172 |
Scr | 0.016 | 0.002 | 1.016(1.012~1.020) | 60.549 | <0.001 |
TC | 0.144 | 0.051 | 1.154(1.044~1.276) | 7.902 | 0.005 |
TG | 0.645 | 0.053 | 1.905(1.716~2.115) | 146.439 | <0.001 |
LDL-C | 0.149 | 0.055 | 1.161(1.041~1.294) | 7.239 | 0.007 |
HDL-C | -3.699 | 0.223 | 0.250(0.160~0.380) | 275.394 | <0.001 |
TyG指数 | 1.213 | 0.094 | 3.365(2.796~4.049) | 165.149 | <0.001 |
TyG-BMI指数 | 0.028 | 0.002 | 1.029(1.025~1.032) | 221.724 | <0.001 |
TyG-WC指数 | 1.310 | 0.074 | 3.705(3.204~4.285) | 311.638 | <0.001 |
TG/HDL-C指数 | 0.398 | 0.027 | 1.489(1.411~1.571) | 211.636 | <0.001 |
Non-HDL-C/HDL-C指数 | 1.110 | 0.063 | 3.034(2.680~3.436) | 126.324 | <0.001 |
METS_IR指数 | 0.205 | 0.012 | 1.228(1.200~1.256) | 308.428 | <0.001 |
LCI指数 | 0.000 | 0.000 | 1.000(1.000~1.000) | 169.924 | <0.001 |
CI指数 | 0.014 | 0.002 | 1.014(1.011~1.017) | 75.331 | <0.001 |
变量 | 模型1 | 模型2 | 模型3 | |||
---|---|---|---|---|---|---|
OR(95%CI) | P值 | OR(95%CI) | P值 | OR(95%CI) | P值 | |
BMI | 1.072(1.021~1.125) | 0.005 | 1.081(1.031~1.133) | <0.001 | ||
WC | 1.130(1.108~1.153) | <0.001 | 1.118(1.097~1.140) | <0.001 | ||
Scr | 1.014(1.010~1.018) | <0.001 | 1.014(1.010~1.018) | <0.001 | 1.014(1.010~1.018) | <0.001 |
TyG指数 | 2.849(2.347~3.561) | <0.001 | ||||
TyG-BMI指数 | 1.018(1.014~1.023) | <0.001 | ||||
TyG-WC指数 | 3.411(2.916~3.991) | <0.001 | ||||
变量 | 模型4 | 模型5 | 模型6 | |||
OR(95%CI) | P值 | OR(95%CI) | P值 | OR(95%CI) | P值 | |
BMI | 1.064(1.013~1.119) | 0.014 | 1.061(1.008~1.116) | <0.001 | ||
WC | 1.132(1.109~1.156) | <0.001 | 1.140(1.116~1.164) | <0.001 | 1.103(1.081~1.125) | <0.001 |
Scr | 1.012(1.008~1.016) | <0.001 | 1.011(1.007~1.015) | <0.001 | 1.013(1.008~1.017) | <0.001 |
TG/HDL-C指数 | 1.425(1.344~1.510) | <0.001 | ||||
Non-HDL-C/HDL-C指数 | 2.847(2.483~3.264) | <0.001 | ||||
METS-IR指数 | 1.170(1.142~1.200) | <0.001 |
Table 4 Multivariate Logistic regression analysis of HUA occurrence in middle-aged and elderly T2DM patients
变量 | 模型1 | 模型2 | 模型3 | |||
---|---|---|---|---|---|---|
OR(95%CI) | P值 | OR(95%CI) | P值 | OR(95%CI) | P值 | |
BMI | 1.072(1.021~1.125) | 0.005 | 1.081(1.031~1.133) | <0.001 | ||
WC | 1.130(1.108~1.153) | <0.001 | 1.118(1.097~1.140) | <0.001 | ||
Scr | 1.014(1.010~1.018) | <0.001 | 1.014(1.010~1.018) | <0.001 | 1.014(1.010~1.018) | <0.001 |
TyG指数 | 2.849(2.347~3.561) | <0.001 | ||||
TyG-BMI指数 | 1.018(1.014~1.023) | <0.001 | ||||
TyG-WC指数 | 3.411(2.916~3.991) | <0.001 | ||||
变量 | 模型4 | 模型5 | 模型6 | |||
OR(95%CI) | P值 | OR(95%CI) | P值 | OR(95%CI) | P值 | |
BMI | 1.064(1.013~1.119) | 0.014 | 1.061(1.008~1.116) | <0.001 | ||
WC | 1.132(1.109~1.156) | <0.001 | 1.140(1.116~1.164) | <0.001 | 1.103(1.081~1.125) | <0.001 |
Scr | 1.012(1.008~1.016) | <0.001 | 1.011(1.007~1.015) | <0.001 | 1.013(1.008~1.017) | <0.001 |
TG/HDL-C指数 | 1.425(1.344~1.510) | <0.001 | ||||
Non-HDL-C/HDL-C指数 | 2.847(2.483~3.264) | <0.001 | ||||
METS-IR指数 | 1.170(1.142~1.200) | <0.001 |
变量 | OR(95%CI) | P值 | |
---|---|---|---|
TyG指数 | Q1 | ||
Q2 | 1.543(0.937~2.149) | <0.084 | |
Q3 | 2.487(1.628~3.346) | <0.001 | |
Q4 | 3.941(2.286~5.435) | <0.001 | |
TyG-BMI指数 | Q1 | ||
Q2 | 2.252(1.420~3.572) | 0.001 | |
Q3 | 2.949(1.883~4.617) | <0.001 | |
Q4 | 4.735(3.035~7.389) | <0.001 | |
TyG-WC指数 | Q1 | ||
Q2 | 2.955(2.201~3.709) | <0.001 | |
Q3 | 3.509(2.462~4.556) | <0.001 | |
Q4 | 5.184(3.850~6.518) | <0.001 | |
TG/HDL-C指数 | Q1 | ||
Q2 | 1.034(0.726~1.342) | 0.297 | |
Q3 | 2.863(2.023~3.703) | <0.001 | |
Q4 | 3.554(2.421~4.687) | <0.001 | |
Non HDL-C/HDL-C指数 | Q1 | ||
Q2 | 1.443(0.720~2.889) | 0.301 | |
Q3 | 2.551(1.482~4.390) | <0.001 | |
Q4 | 4.375(2.337~8.192) | <0.001 | |
METS-IR指数 | Q1 | ||
Q2 | 2.568(1.526~4.322) | <0.001 | |
Q3 | 3.473(2.097~5.752) | <0.001 | |
Q4 | 4.725(2.453~6.997) | <0.001 |
Table 5 Multivariate Logistic regression analysis of 6 insulin resistance replacement indexes for the occurrence of HUA
变量 | OR(95%CI) | P值 | |
---|---|---|---|
TyG指数 | Q1 | ||
Q2 | 1.543(0.937~2.149) | <0.084 | |
Q3 | 2.487(1.628~3.346) | <0.001 | |
Q4 | 3.941(2.286~5.435) | <0.001 | |
TyG-BMI指数 | Q1 | ||
Q2 | 2.252(1.420~3.572) | 0.001 | |
Q3 | 2.949(1.883~4.617) | <0.001 | |
Q4 | 4.735(3.035~7.389) | <0.001 | |
TyG-WC指数 | Q1 | ||
Q2 | 2.955(2.201~3.709) | <0.001 | |
Q3 | 3.509(2.462~4.556) | <0.001 | |
Q4 | 5.184(3.850~6.518) | <0.001 | |
TG/HDL-C指数 | Q1 | ||
Q2 | 1.034(0.726~1.342) | 0.297 | |
Q3 | 2.863(2.023~3.703) | <0.001 | |
Q4 | 3.554(2.421~4.687) | <0.001 | |
Non HDL-C/HDL-C指数 | Q1 | ||
Q2 | 1.443(0.720~2.889) | 0.301 | |
Q3 | 2.551(1.482~4.390) | <0.001 | |
Q4 | 4.375(2.337~8.192) | <0.001 | |
METS-IR指数 | Q1 | ||
Q2 | 2.568(1.526~4.322) | <0.001 | |
Q3 | 3.473(2.097~5.752) | <0.001 | |
Q4 | 4.725(2.453~6.997) | <0.001 |
变量 | AUC | OR(95%CI) | 灵敏度(%) | 特异度(%) | 最佳截断值 | 约登指数 |
---|---|---|---|---|---|---|
TyG指数 | 0.677 | (0.650,0.703) | 89.80 | 65.30 | 8.78 | 0.245 |
TyG-BMI指数 | 0.731 | (0.706,0.756) | 59.50 | 25.90 | 234.90 | 0.336 |
TyG-WC指数 | 0.811 | (0.792,0.830) | 84.80 | 37.90 | 8.20 | 0.469 |
TG/HDL-C指数 | 0.757 | (0.733,0.780) | 82.30 | 45.70 | 2.28 | 0.366 |
Non-HDL-C/HDL-C指数 | 0.796 | (0.773,0.819) | 77.50 | 30.30 | 2.76 | 0.472 |
METS-IR指数 | 0.791 | (0.768,0.814) | 64.50 | 22.00 | 39.61 | 0.425 |
男性 | ||||||
TyG指数 | 0.655 | (0.622,0.688) | 88.70 | 65.90 | 8.77 | 0.228 |
TyG-BMI指数 | 0.701 | (0.669,0.733) | 58.60 | 29.70 | 234.48 | 0.289 |
TyG-WC指数 | 0.770 | (0.742,0.797) | 72.60 | 34.10 | 8.46 | 0.385 |
TG/HDL-C指数 | 0.733 | (0.703,0.763) | 84.20 | 49.30 | 2.28 | 0.349 |
Non-HDL-C/HDL-C指数 | 0.785 | (0.756,0.814) | 75.90 | 30.70 | 2.82 | 0.452 |
METS-IR指数 | 0.765 | (0.735,0.795) | 62.80 | 23.30 | 40.16 | 0.395 |
女性 | ||||||
TyG指数 | 0.719 | (0.675,0.763) | 66.40 | 37.00 | 9.20 | 0.294 |
TyG-BMI指数 | 0.770 | (0.737,0.817) | 67.80 | 25.50 | 232.53 | 0.423 |
TyG-WC指数 | 0.864 | (0.838,0.890) | 87.40 | 26.80 | 8.28 | 0.606 |
TG/HDL-C指数 | 0.782 | (0.742,0.822) | 51.70 | 11.90 | 3.97 | 0.398 |
Non-HDL-C/HDL-C指数 | 0.808 | (0.771,0.845) | 78.30 | 26.70 | 2.76 | 0.516 |
METS-IR指数 | 0.822 | (0.786,0.857) | 81.80 | 33.00 | 36.81 | 0.488 |
Table 6 ROC curve and subgroup analysis of different insulin resistance replacement indexes for the risk of HUA in T2DM patients
变量 | AUC | OR(95%CI) | 灵敏度(%) | 特异度(%) | 最佳截断值 | 约登指数 |
---|---|---|---|---|---|---|
TyG指数 | 0.677 | (0.650,0.703) | 89.80 | 65.30 | 8.78 | 0.245 |
TyG-BMI指数 | 0.731 | (0.706,0.756) | 59.50 | 25.90 | 234.90 | 0.336 |
TyG-WC指数 | 0.811 | (0.792,0.830) | 84.80 | 37.90 | 8.20 | 0.469 |
TG/HDL-C指数 | 0.757 | (0.733,0.780) | 82.30 | 45.70 | 2.28 | 0.366 |
Non-HDL-C/HDL-C指数 | 0.796 | (0.773,0.819) | 77.50 | 30.30 | 2.76 | 0.472 |
METS-IR指数 | 0.791 | (0.768,0.814) | 64.50 | 22.00 | 39.61 | 0.425 |
男性 | ||||||
TyG指数 | 0.655 | (0.622,0.688) | 88.70 | 65.90 | 8.77 | 0.228 |
TyG-BMI指数 | 0.701 | (0.669,0.733) | 58.60 | 29.70 | 234.48 | 0.289 |
TyG-WC指数 | 0.770 | (0.742,0.797) | 72.60 | 34.10 | 8.46 | 0.385 |
TG/HDL-C指数 | 0.733 | (0.703,0.763) | 84.20 | 49.30 | 2.28 | 0.349 |
Non-HDL-C/HDL-C指数 | 0.785 | (0.756,0.814) | 75.90 | 30.70 | 2.82 | 0.452 |
METS-IR指数 | 0.765 | (0.735,0.795) | 62.80 | 23.30 | 40.16 | 0.395 |
女性 | ||||||
TyG指数 | 0.719 | (0.675,0.763) | 66.40 | 37.00 | 9.20 | 0.294 |
TyG-BMI指数 | 0.770 | (0.737,0.817) | 67.80 | 25.50 | 232.53 | 0.423 |
TyG-WC指数 | 0.864 | (0.838,0.890) | 87.40 | 26.80 | 8.28 | 0.606 |
TG/HDL-C指数 | 0.782 | (0.742,0.822) | 51.70 | 11.90 | 3.97 | 0.398 |
Non-HDL-C/HDL-C指数 | 0.808 | (0.771,0.845) | 78.30 | 26.70 | 2.76 | 0.516 |
METS-IR指数 | 0.822 | (0.786,0.857) | 81.80 | 33.00 | 36.81 | 0.488 |
变量 | HUA | NHUA | 合计 |
---|---|---|---|
TyG-WC指数 | |||
高 | 42 | 371 | 413 |
低 | 32 | 510 | 542 |
合计 | 74 | 881 | 955 |
Non-HDL-C/HDL-C指数 | |||
高 | 46 | 430 | 476 |
低 | 28 | 451 | 479 |
合计 | 74 | 881 | 955 |
METS-IR指数 | |||
高 | 36 | 318 | 354 |
低 | 38 | 563 | 601 |
合计 | 74 | 881 | 955 |
Table 7 Nested case-control analysis of HUA occurrence
变量 | HUA | NHUA | 合计 |
---|---|---|---|
TyG-WC指数 | |||
高 | 42 | 371 | 413 |
低 | 32 | 510 | 542 |
合计 | 74 | 881 | 955 |
Non-HDL-C/HDL-C指数 | |||
高 | 46 | 430 | 476 |
低 | 28 | 451 | 479 |
合计 | 74 | 881 | 955 |
METS-IR指数 | |||
高 | 36 | 318 | 354 |
低 | 38 | 563 | 601 |
合计 | 74 | 881 | 955 |
变量 | 血糖控制不佳 | 血糖控制良好 | 合计 |
---|---|---|---|
TyG-WC指数 | |||
高 | 221 | 192 | 413 |
低 | 145 | 397 | 542 |
合计 | 366 | 589 | 955 |
Non-HDL-C/HDL-C指数 | |||
高 | 216 | 260 | 476 |
低 | 150 | 329 | 479 |
合计 | 366 | 589 | 955 |
METS-IR指数 | |||
高 | 186 | 168 | 354 |
低 | 180 | 421 | 601 |
合计 | 366 | 589 | 955 |
Table 8 Nested case-control study of blood glucose control in diabetic patients
变量 | 血糖控制不佳 | 血糖控制良好 | 合计 |
---|---|---|---|
TyG-WC指数 | |||
高 | 221 | 192 | 413 |
低 | 145 | 397 | 542 |
合计 | 366 | 589 | 955 |
Non-HDL-C/HDL-C指数 | |||
高 | 216 | 260 | 476 |
低 | 150 | 329 | 479 |
合计 | 366 | 589 | 955 |
METS-IR指数 | |||
高 | 186 | 168 | 354 |
低 | 180 | 421 | 601 |
合计 | 366 | 589 | 955 |
[1] |
|
[2] |
中华医学会糖尿病学分会胰岛素抵抗学组(筹). 胰岛素抵抗评估方法和应用的专家指导意见[J]. 中华糖尿病杂志,2018,10(6):377-385. DOI:10.3760/cma.j.issn.1674-5809.2018.06.001.
|
[3] |
|
[4] |
|
[5] |
|
[6] |
|
[7] |
|
[8] |
|
[9] |
|
[10] |
宋华隆,高鹰. 血尿酸水平与2型糖尿病发病风险的关联队列研究[J]. 中国全科医学,2023,26(15):1831-1839. DOI:10.12114/j.issn.1007-9572.2022.0785.
|
[11] |
段琼,张紫行,徐娟,等. 高尿酸血症与脂肪肝关联的前瞻性队列研究[J]. 中华疾病控制杂志,2022,26(12):1420-1425,1432. DOI:10.16462/j.cnki.zhjbkz.2022.12.010.
|
[12] |
|
[13] |
李歆旎,沈艳,金雪娟,等. 血尿酸与高血压的相关性研究[J]. 中国分子心脏病学杂志,2022,22(5):4897-4902. DOI:10.16563/j.cnki.1671-6272.2022.10.005.
|
[14] |
|
[15] |
|
[16] |
中华医学会糖尿病学分会. 中国2型糖尿病防治指南(2020年版)[J]. 国际内分泌代谢杂志,2021,41(5):482-548. DOI:10.3760/cma.j.cn121383-20210825-08063.
|
[17] |
中华医学会内分泌学分会. 中国高尿酸血症与痛风诊疗指南(2019)[J]. 中华内分泌代谢杂志,2020,36(1):1-13. DOI:10.3760/cma.j.issn.1000-6699.2020.01.001.
|
[18] | |
[19] |
中国疾病预防控制中心. 中国慢性病及其危险因素监测分析报告2004年[M]. 北京:中国协和医科大学出版社,2009.
|
[20] |
|
[21] | |
[22] |
|
[23] |
刘颖. 高尿酸对3T3-L1脂肪细胞IRS-1表达及其酪氨酸磷酸化水平的影响[D]. 长沙:中南大学,2013.
|
[24] |
董洋,赵心迪,曹慧霞,等. 2型糖尿病患者血尿酸水平与肾功能损伤的相关性[J]. 中华实用诊断与治疗杂志,2022,36(5):456-459. DOI:10.13507/j.issn.1674-3474.2022.05.005.
|
[25] |
|
[26] |
|
[27] |
|
[28] |
|
[29] |
|
[30] | |
[31] |
|
[32] |
|
[33] |
|
[34] |
|
[35] |
|
[36] |
|
[37] |
|
[38] |
杨媛,周光清,李宛霖,等. 不同肥胖指标在高尿酸血症风险预测中的应用价值比较研究[J]. 中国全科医学,2022,25(4):453-460. DOI:10.12114/j.issn.1007-9572.2021.00.281.
|
[39] |
|
[40] |
|
[41] |
|
[42] |
|
[43] |
|
[44] |
|
[45] | |
[46] |
赵美茹,朱迪,刘淋,等. 简易胰岛素抵抗指标与698例2型糖尿病患者发生高尿酸血症风险的关联[J]. 山东大学学报(医学版),2022,60(12):44-51. DOI:10.6040/j.issn.1671-7554.0.2022.0575.
|
[1] | XU Jialan, YAN Hong, WEN Jun, ZHOU Zitong, WANG Siyu. Prevalence of Potentially Inappropriate Medication in Older Adults with Cancer: a Meta-analysis [J]. Chinese General Practice, 2025, 28(30): 3815-3822. |
[2] | LI Ling, LI Yaping, QIAN Shixing, NIE Jing, LU Chunhua, LI Xia. Research on Influencing Factors and Risk Prediction of Cognitive Function in Community-dwelling Middle-aged and Elderly People [J]. Chinese General Practice, 2025, 28(30): 3773-3778. |
[3] | ZHOU Penglong, CHANG Jing, DING Suying, CHEN Jingfeng, WANG Tao, LI Chenyang. Correlation Analysis between Age-Stratified Differences in Fat-to-muscle Ratio and Hyperuricemia [J]. Chinese General Practice, 2025, 28(27): 3375-3384. |
[4] | YU Wenhua, LI Jianguo, DUAN Wenyan, GAO Xuyan, LI Xiaxia, ZHANG Zilong, ZHANG Li, MA Lina. Reliability and Validity of the Function Impairment Screening Tool among Community-dwelling Older Adults [J]. Chinese General Practice, 2025, 28(24): 3000-3004. |
[5] | YANG Chen, CHEN Tong, ZHANG Lifang, ZHANG Hongxu, LI Pengfei, ZHANG Xuejuan. Prognostic Impact of Dapagliflozin in Elderly Breast Cancer Survivors with Heart Failure with Preserved Ejection Fraction and Type 2 Diabetes [J]. Chinese General Practice, 2025, 28(24): 3053-3058. |
[6] | LI Jiaxin, LIU Zhonghui, XIE Shuo, FU Zhifang, SUN Dan, JIAO Hongmei. Trajectory in Biomarkers of Metabolic and Inflammatory States as Early Predictors of Chronic Critical Illness in Aging Patients [J]. Chinese General Practice, 2025, 28(24): 2993-2999. |
[7] | LIU Yueying, WANG Xueli, LIU Yuqiu, WEI Limin. Correlation of Fasting C-peptide to Diabetes Duration Ration and Type 2 Diabetes Mellitus Combined with Metabolism-related Fatty Liver Disease [J]. Chinese General Practice, 2025, 28(23): 2852-2860. |
[8] | ZHAO Xiaoqing, GUO Tongtong, ZHANG Xinyi, LI Linhong, ZHANG Ya, JI Lihong, DONG Zhiwei, GAO Qianqian, CAI Weiqing, ZHENG Wengui, JING Qi. Construction and Validation of a Risk Prediction Model for Cognitive Impairment in Community-dwelling Older Adults [J]. Chinese General Practice, 2025, 28(22): 2776-2783. |
[9] | SHI Xiaotian, WANG Shan, YANG Huayu, YANG Yifan, LI Xu, MA Qing. Association between Body Mass Index and Mortality among Older Chinese: a Cohort Study [J]. Chinese General Practice, 2025, 28(22): 2791-2797. |
[10] | LIU Meixia, YIN Jinnian, WU Mei, YANG Xing, ZHOU Quanxiang, YANG Jingyuan. Impact of Body Mass Index on the Association of Triglyceride Glucose Index with Cognitive Function: a Cross-sectional Study in Rural Older Adults in Guizhou Province [J]. Chinese General Practice, 2025, 28(22): 2806-2812. |
[11] | LIANG Hengmiao, HUANG Sizhe, CHEN Yuting, LIU Ce, WANG Huijun, DU Qingfeng. A Retrospective Analysis of the Association between Serum Uric Acid Levels and Insulin Resistance Degrees in Individuals Undergoing Health Examination [J]. Chinese General Practice, 2025, 28(21): 2635-2642. |
[12] | HAO Aihua, ZENG Ziying, JIN Aiqiong, TANG Lingling, ZHENG Zique, MA Jingtai, ZHAO Jianguo, ZENG Weilin, XIAO Jianpeng, NIE Hui, YANG Ying. Analysis of Factors Influencing Avoidable Hospitalization for Elderly Hypertensive Patients [J]. Chinese General Practice, 2025, 28(19): 2370-2375. |
[13] | WANG Zhijun, ZHANG Shibo, LIU Jie, LI Dongqi, ZHENG Meijia, ZHOU Jianzhi. Correlation Analysis between TyG-BMI Index and Nocturnal Hypertension in Patients with Hypertension [J]. Chinese General Practice, 2025, 28(18): 2212-2221. |
[14] | HAN Zheng, SUN Meng, FU Fanglin, PAN Yaojia, WANG Weiqiang. A Study on the Relationship between the Triglyceride-Glucose Index and Cardiometabolic Multimorbidity in Individuals Aged 50 and Above [J]. Chinese General Practice, 2025, 28(18): 2278-2284. |
[15] | CHEN Qiaoqiao, SU Ping, ZHAO Yingying, PANG Jinhong, SHI Jie, WANG Yaqian, LI Qiuchun, HE Ruiyan, WANG Yue, CHEN Xueyu, QIAO Junpeng, CHI Weiwei. Association between Triglyceride-Glucose Index and Incident Cardiometabolic Multimorbidity in the Elderly: a Prospective Cohort Study [J]. Chinese General Practice, 2025, 28(18): 2270-2277. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||